PE20050438A1 - Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos - Google Patents

Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos

Info

Publication number
PE20050438A1
PE20050438A1 PE2004000975A PE2004000975A PE20050438A1 PE 20050438 A1 PE20050438 A1 PE 20050438A1 PE 2004000975 A PE2004000975 A PE 2004000975A PE 2004000975 A PE2004000975 A PE 2004000975A PE 20050438 A1 PE20050438 A1 PE 20050438A1
Authority
PE
Peru
Prior art keywords
treatment
milano
coronary syndromes
prevention
apo
Prior art date
Application number
PE2004000975A
Other languages
English (en)
Inventor
Wendi V Rodrigueza
Daniel Hartman
Narendra D Lalwani
Charles L Bisgaier
Jan Johansson
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of PE20050438A1 publication Critical patent/PE20050438A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN METODO PARA EL TRATAMIENTO DE SINDROMES CORONARIOS MEDIANTE LA ADMINISTRACION DE UNA APOLIPROTEINA A-I MILANO: 1-PALMITOIL-2-OLEOIL-sn-GLICERO-3-COMPLEJO FOSFOCHOLOINA (APO A-I MILANO: COMPLEJO POPC) EN UNA DOSIS DE 1mg DE PROTEINA/kg A 100 mg DE PROTEINA/kg. LA DOSIS PUEDE SER DE 15 mg/kg, 45 mg/kg. LA APO A-I MILANO ES APO A-I MILANO RECOMBINANTE. SE REFIERE TAMBIEN A UNA FORMULACION FARMACEUTICA LIQUIDA ESTERIL QUE ES ADMINISTRADA A UN SUJETO A UNA DOSIS DE 15mg/kg A 45 mg/kg UNA VEZ POR SEMANA POR APROXIMADAMENTE 6 MESES, 5 MESES, ENTRE OTROS. LA FORMULACION COMPRENDE APO A-I MILANO, POPC, UN PORTADOR SACAROSA-MANITOL, UN COMPENSADOR FOSFATO DONDE EL PORTADOR SACAROSA-MANITOL ES DE 6% A 6,4% DE SACAROSA Y 0,8% A 1% DE MANITOL Y LA FORMULACION TIENE UN PH 7 A 7,68. LA FORMULACION ES UTIL PARA EL TRATAMIENTO Y LA PREVENCION DE SINDROMES CORONARIOS AGUDOS
PE2004000975A 2003-10-20 2004-10-11 Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos PE20050438A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51311603P 2003-10-20 2003-10-20
US51701603P 2003-11-03 2003-11-03
US57112904P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
PE20050438A1 true PE20050438A1 (es) 2005-06-14

Family

ID=34557347

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000975A PE20050438A1 (es) 2003-10-20 2004-10-11 Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos

Country Status (24)

Country Link
US (2) US7435717B2 (es)
EP (1) EP1677597B1 (es)
JP (1) JP2007509157A (es)
KR (3) KR20070110561A (es)
AR (1) AR046126A1 (es)
AU (2) AU2004284932A1 (es)
CA (1) CA2542726C (es)
CO (1) CO5690611A2 (es)
CR (1) CR8352A (es)
EA (1) EA010134B1 (es)
EC (1) ECSP066516A (es)
ES (1) ES2449719T3 (es)
GE (1) GEP20094601B (es)
HK (1) HK1093869A1 (es)
IL (1) IL174301A (es)
MA (1) MA28102A1 (es)
MX (1) MXPA06004362A (es)
NO (1) NO339456B1 (es)
NZ (1) NZ545939A (es)
OA (1) OA13272A (es)
PA (1) PA8615301A1 (es)
PE (1) PE20050438A1 (es)
RS (1) RS20060273A (es)
WO (1) WO2005041866A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US8377114B2 (en) 1999-08-09 2013-02-19 Cardiokinetix, Inc. Sealing and filling ventricular partitioning devices to improve cardiac function
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US8246671B2 (en) 1999-08-09 2012-08-21 Cardiokinetix, Inc. Retrievable cardiac devices
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
CN1943790A (zh) * 2001-09-28 2007-04-11 埃斯佩里安医疗公司 通过局部给药预防和治疗再狭窄
AU2003239489A1 (en) * 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
EP1732383A4 (en) * 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH VIRUS VECTORS ASSOCIATED WITH RECOMBINANT ADENOVIRUS CODING APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
CN101227908A (zh) * 2005-07-22 2008-07-23 宝洁公司 用于减少药源性心律失常发生的组合物
EP1986735A4 (en) * 2006-02-06 2011-06-29 Northwind Ventures SYSTEMS AND METHODS FOR VOLUME REDUCTION
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
MX2008011261A (es) * 2006-03-03 2008-10-28 Activbiotics Pharma Llc Tratamiento de la enfermedad aterosclerotica.
DE102007006663A1 (de) * 2007-02-10 2008-08-21 Lts Lohmann Therapie-Systeme Ag Transport von Arzneistoffen über die Blut-Hirn-Schranke mittels Apolipoproteinen
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
WO2010033878A2 (en) 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
DK2398502T3 (en) * 2009-02-18 2015-11-23 Cormatrix Cardiovascular Inc FORMATIONS AND PROCESSES FOR PREVENTING cardiac arrhythmia
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
AU2010217760B2 (en) 2009-02-27 2015-04-09 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US20100234827A1 (en) * 2009-03-13 2010-09-16 Sigg Daniel C Method of treating heart failure
US8758323B2 (en) 2009-07-30 2014-06-24 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
JP5875986B2 (ja) 2009-10-26 2016-03-02 カーディオキネティックス・インコーポレイテッドＣａｒｄｉｏｋｉｎｅｔｉｘ， Ｉｎｃ． 心室容積縮小
CN105396122B (zh) 2010-06-30 2020-09-11 杰特有限公司 重建高密度脂蛋白制剂及其生产方法
CA2807448A1 (en) 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Tetranectin-apolipoprotein a-i, lipid particles containing it and its use
MX2013001539A (es) 2010-08-30 2013-03-18 Hoffmann La Roche Metodo para producir una particula de tetranectina-apolipoproteina a-1, la particula lipidica obtenida por el mismoy su uso.
BR112013004397A2 (pt) 2010-08-30 2017-06-27 Hoffmann La Roche método para produzir uma partícula de lipídio, a partícula de lipídio em si e seu uso
IN2013DN07828A (es) 2011-02-07 2015-07-03 Cerenis Therapeutics Holding S A
JP6203707B2 (ja) * 2011-04-27 2017-09-27 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アポリポタンパク質ｃｉｉｉ（ａｐｏｃｉｉｉ）発現の調節
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
JP6207507B2 (ja) 2011-08-25 2017-10-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 短縮されたテトラネクチン−アポリポプロテインａ−ｉ融合タンパク質、それを含む脂質粒子、及びその使用
EP2793913B1 (en) * 2011-12-21 2023-06-21 CSL Limited Dosage regime for apolipoprotein formulations
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
CN105050614B (zh) 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
HUE039246T2 (hu) * 2013-10-31 2018-12-28 Novo Nordisk As Injekciós készülék tûkanüllel
CA2962747C (en) 2014-09-28 2023-02-28 Cardiokinetix, Inc. Apparatuses for treating cardiac dysfunction
US10668015B2 (en) * 2015-01-20 2020-06-02 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
PL3341044T3 (pl) * 2015-08-25 2020-06-01 Novo Nordisk A/S Wyrób medyczny do iniekcji z komorą czyszczącą
DE102018107407A1 (de) 2017-03-28 2018-10-04 Edwards Lifesciences Corporation Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US6306433B1 (en) * 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
CN1943790A (zh) * 2001-09-28 2007-04-11 埃斯佩里安医疗公司 通过局部给药预防和治疗再狭窄
MXPA04011227A (es) * 2002-05-17 2005-01-25 Esperion Therapeutics Inc Metodos y composiciones para el tratamiento de la reperfusion isquemica.
AU2003239489A1 (en) * 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders

Also Published As

Publication number Publication date
AU2011202014A1 (en) 2011-05-26
EA010134B1 (ru) 2008-06-30
AU2004284932A1 (en) 2005-05-12
KR20060080227A (ko) 2006-07-07
NO339456B1 (no) 2016-12-12
OA13272A (en) 2007-01-31
NZ545939A (en) 2008-08-29
EP1677597B1 (en) 2014-01-08
US7435717B2 (en) 2008-10-14
ECSP066516A (es) 2006-11-24
WO2005041866A3 (en) 2006-05-18
PA8615301A1 (es) 2005-09-28
CR8352A (es) 2007-03-02
ES2449719T3 (es) 2014-03-20
EA200600548A1 (ru) 2006-10-27
KR20100101710A (ko) 2010-09-17
IL174301A0 (en) 2006-08-01
IL174301A (en) 2013-09-30
AR046126A1 (es) 2005-11-23
JP2007509157A (ja) 2007-04-12
WO2005041866A2 (en) 2005-05-12
CA2542726C (en) 2012-05-15
AU2011202014B2 (en) 2012-06-14
EP1677597A2 (en) 2006-07-12
CA2542726A1 (en) 2005-05-12
KR20070110561A (ko) 2007-11-19
GEP20094601B (en) 2009-02-10
RS20060273A (sr) 2008-09-29
NO20062110L (no) 2006-07-18
MA28102A1 (fr) 2006-08-01
EP1677597A4 (en) 2011-08-24
MXPA06004362A (es) 2006-09-04
CO5690611A2 (es) 2006-10-31
HK1093869A1 (en) 2007-03-16
US20050142180A1 (en) 2005-06-30
US20080293633A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
PE20050438A1 (es) Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
JP7159277B2 (ja) 即効型インスリン組成物
EP2575761B1 (en) Stable multi-dose compositions comprising an antibody and a preservative
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
DE69636531D1 (de) Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
TR200502189T1 (tr) Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
MA28152A1 (fr) Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
SI1687019T1 (en) PROPILED GLIKO-CONTAINING PEPTIDAL FORMULATIONS OPTIMAL FOR MANUFACTURING AND FOR USE IN INJECTION DEVICES
EA200601253A1 (ru) Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
BR0007974A (pt) Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
HK1076401A1 (en) Liquid pharmaceutical formulations of palonosetron
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
MX2021014332A (es) Formulaciones estabilizadas que contienen anticuerpos anti-angptl3.
WO2001047913A3 (de) Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung
AR042543A1 (es) Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroides
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
IL310909A (en) Dosing regimens associated with delayed-release injectable formulations of paliperidone
SE0203817D0 (sv) New composition
AR045074A1 (es) Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
BR112021016795A8 (pt) Administração de inibidor de enzima de ativação de sumo e inibidores de checkpoint
GEP20053581B (en) Pharmaceutical Composition and Method for Preparation Thereof
DE69902925D1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen

Legal Events

Date Code Title Description
FC Refusal